Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 17INDUSTRY 7NETWORK 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Osteosarcoma 1Melanoma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 87Cyclophosphamide 84Cisplatin 79Doxorubicin 66Vincristine 62Paclitaxel 55Etoposide 50Carboplatin 49Filgrastim 48Methotrexate 41Prednisone 40Cytarabine 37Granulocyte Colony-Stimulating Factor 35Radiotherapy, Intensity-Modulated 31Platinum 31Docetaxel 31Gemcitabine 30Leucovorin 28Dexamethasone 28Radiotherapy, Conformal 27Fluorouracil 27Cetuximab 26Taxes 24Rituximab 23Irinotecan 231,2-diaminocyclohexaneplatinum II citrate 23Radiation 21merphos 20Bevacizumab 19Temozolomide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Has results × peginterferon alfa-2b × Clear all
NCT00049530 2023-06-29

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Eastern Cooperative Oncology Group

Phase 2 Completed
32 enrolled 8 charts
Dermatologic

Melanoma

NCT00134030 2023-06-07

EURAMOS-1

Children's Oncology Group

Phase 3 Completed
1,334 enrolled 17 charts
Sarcoma

Osteosarcoma

NCT00467077 2017-03-17

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

California Cancer Consortium

Phase 2 Terminated
21 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡